Literature DB >> 33450864

Factors Associated with Refusal or Discontinuation of Treatment in Patients with Bladder Cancer: A Cohort Population-Based Study in Taiwan.

Nai-Tan Chang1,2, Ying-Hsu Chang3,4,5, Yu-Tung Huang6, Shu-Ching Chen2,7,8.   

Abstract

Cancer treatment causes adverse effects that lead to refusal or discontinuation of treatment. The purposes of this study were to identify 1) the factors associated with and 2) the reasons for refusing and discontinuing treatment in patients with bladder cancer (BC). We conducted a retrospective cohort study in patients diagnosed with BC in Taiwan from 1 January 2014 to 30 June 2019 using a linked cancer registry database. Of the 1247 BC patients in the study cohort, 2.1% reported refusing treatment. Patients with less education and those diagnosed at cancer stage II-IV were more likely to refuse treatment. The major reason for refusing treatment was "patient or the family considered patient's poor physical condition (chronic disease or unstable systemic disease), difficulty in enduring any condition likely to cause physical discomfort from disease treatment". A total of 4.3% of BC patients reported discontinuing treatment. Patients not living in the northern region of Taiwan and those diagnosed at cancer stage II-IV were more likely to terminate treatment before completion. The major reason given for discontinuing treatment was inconvenient transportation. Sufficient social resources and supportive care can help BC patients cope with the physical and psychological burden of treatment.

Entities:  

Keywords:  bladder cancer; case management; discontinuing treatment; patient non-compliance; refusing treatment

Year:  2021        PMID: 33450864      PMCID: PMC7828302          DOI: 10.3390/ijerph18020618

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  18 in total

Review 1.  Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.

Authors:  G Arcangeli; L Strigari; S Arcangeli
Journal:  Crit Rev Oncol Hematol       Date:  2015-04-17       Impact factor: 6.312

2.  Factors impacting on discordance with treatment plan in head and neck cancer patients: a retrospective, population-based cohort study.

Authors:  Ya-Lan Chang; Shu-Chu Lee; Chun-Ta Liao; Chao-Hui Wang; Yu-Fen Lin; Shu-Ching Chen
Journal:  Support Care Cancer       Date:  2019-06-08       Impact factor: 3.603

3.  Race and health disparities in patient refusal of surgery for early-stage non-small cell lung cancer: a SEER cohort study.

Authors:  Rohtesh S Mehta; Diana Lenzner; Athanassios Argiris
Journal:  Ann Surg Oncol       Date:  2011-09-27       Impact factor: 5.344

4.  Treatment interruption during radiation therapy: Experience at a single institution in the Republic of Korea.

Authors:  Jung Ae Lee; Nam Kwon Lee; Won Sup Yoon; Dae Sik Yang; Chul Yong Kim; Se Ryun Lee; Hwa Jeong Seong
Journal:  Asia Pac J Clin Oncol       Date:  2016-08-04       Impact factor: 2.601

5.  Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.

Authors:  Friedemann Honecker; Ulrich Wedding; Gerd Kallischnigg; Axel Schroeder; Jörg Klier; Thomas Frangenheim; Lothar Weißbach
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-04       Impact factor: 4.553

6.  Colorectal cancer in Taiwan: A case-control retrospective analysis of the impact of a case management programme on refusal and discontinuation of treatment.

Authors:  Ting-Yu Chiang; Chao-Hui Wang; Yu-Fen Lin; Jeng-Fu You; Jinn-Shiun Chen; Shu-Ching Chen
Journal:  J Adv Nurs       Date:  2017-10-04       Impact factor: 3.187

7.  Physicians' evaluations of patients' decisions to refuse oncological treatment.

Authors:  T van Kleffens; E van Leeuwen
Journal:  J Med Ethics       Date:  2005-03       Impact factor: 2.903

8.  Factors associated with radiation therapy incompletion for patients with early-stage breast cancer.

Authors:  Rachel A Freedman; Stacey A Fedewa; Rinaa S Punglia; Chun Chieh Lin; Elizabeth M Ward; Ahmedin Jemal; Helmneh M Sineshaw
Journal:  Breast Cancer Res Treat       Date:  2015-12-18       Impact factor: 4.872

9.  Head and neck radiotherapy compliance in an underserved patient population.

Authors:  Rajni A Sethi; Emily F Stamell; Leah Price; Mark DeLacure; Nicholas Sanfilippo
Journal:  Laryngoscope       Date:  2010-07       Impact factor: 3.325

10.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.